...
首页> 外文期刊>Journal of Cellular Physiology >Whether to target single or multiple CDKs for therapy? That is the question.
【24h】

Whether to target single or multiple CDKs for therapy? That is the question.

机译:是否以单个或多个CDKs为目标治疗呢?

获取原文
获取原文并翻译 | 示例
           

摘要

Complexes consisting of cyclin-dependent kinases (CDKs) and their regulatory subunits (the cyclins) control the progression of normal mammalian cells through the cell cycle. However, during malignant transformation this regulatory apparatus malfunctions, allowing cells to undergo unchecked proliferation. In many cases, the high mitotic potential of malignant cells is due to the constitutive activation of CDK-cyclin complexes, facilitated by the inactivation of cellular CDK inhibitors, such as p16(INK4A) or p27(Kip1), and the loss of functional tumor suppressors, such as the p53 and pRb proteins. It has recently been suggested that pharmacological intervention based on remedying the deficiency or loss of activity of these negative regulators of the cell cycle could be a very effective therapeutic option in the treatment of cancer. Multiple CDK inhibitors have been synthesized over the last two decades, spanning at least five classes of compounds. While these inhibitors can be classified on the basis of their chemical structure, it may be more interesting to categorize them according to their pharmacological nature, as broad-spectrum unspecific, pan-specific, or very selective antagonists. This review offers a critical assessment of the advantages and disadvantages of both pan-specific and highly selective CDK inhibitors in therapy.
机译:细胞周期蛋白依赖性激酶组成的复合物(CDKs)及其管理单元(细胞周期蛋白)控制正常的发展哺乳动物细胞通过细胞周期。在恶性转变这一监管设备故障,使细胞发生不扩散。有丝分裂是由于潜在的恶性细胞CDK-cyclin的本构激活复合物,失活的了细胞CDK抑制剂,如p16 (INK4A)或p27 (Kip1)和功能性肿瘤抑制,如蛋白质p53和复审委员会。最近表明,药理吗基于桥面铺装不足或干预这些消极的监管机构的活动细胞周期可能是非常有效的在治疗癌症的治疗选项。多个CDK抑制剂已被合成在过去的二十年里,生成至少5个类化合物。被分类的基础上,他们的化学结构,它可能会更有趣根据他们对它们进行归类广谱的药理性质非特定的、pan-specific或非常挑剔拮抗剂。评估的优点和缺点pan-specific和高度选择性CDK抑制剂治疗。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号